RT Journal Article
SR Electronic
T1 Enhancing Chemotherapy Response Prediction via Matched Colorectal Tumor-Organoid Gene Expression Analysis and Network-Based Biomarker Selection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.24.24301749
DO 10.1101/2024.01.24.24301749
A1 Zhang, Wei
A1 Wu, Chao
A1 Huang, Hanchen
A1 Bleu, Paulina
A1 Zambare, Wini
A1 Alvarez, Janet
A1 Wang, Lily
A1 Paty, Philip B.
A1 Romesser, Paul B.
A1 Smith, J. Joshua
A1 Chen, X. Steven
YR 2024
UL http://medrxiv.org/content/early/2024/05/09/2024.01.24.24301749.abstract
AB Colorectal cancer (CRC) poses significant challenges in chemotherapy response prediction due to its molecular heterogeneity. This study introduces an innovative methodology that leverages gene expression data generated from matched colorectal tumor and organoid samples to enhance prediction accuracy. By applying Consensus Weighted Gene Co-expression Network Analysis (WGCNA) across multiple datasets, we identify critical gene modules and hub genes that correlate with patient responses, particularly to 5-fluorouracil (5-FU). This integrative approach advances precision medicine by refining chemotherapy regimen selection based on individual tumor profiles. Our predictive model demonstrates superior accuracy over traditional methods on independent datasets, illustrating significant potential in addressing the complexities of high-dimensional genomic data for cancer biomarker research.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by US National Cancer Institute grant R37CA248289 (J.J.S), and Sylvester Comprehensive Cancer Center Intramural program SCCC-NIH-2022-11 (X.S.C).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All datasets used in the study are publicly available data from Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/) and NCI Genomic Data Commons Data Portal (https://portal.gdc.cancer.gov/)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll datasets used in the study are publicly available data from Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/) and NCI Genomic Data Commons Data Portal (https://portal.gdc.cancer.gov/) https://www.ncbi.nlm.nih.gov/geo/ https://portal.gdc.cancer.gov/